Genocea Biosciences, Inc. (GNCA)
(Delayed Data from NSDQ)
$0.70 USD
+0.01 (0.73%)
Updated May 3, 2019 04:13 PM ET
After-Market: $0.70 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Genocea Biosciences, Inc. [GNCA]
Reports for Purchase
Showing records 1 - 20 ( 46 total )
Company: Genocea Biosciences, Inc.
Industry: Medical - Drugs
Company: Genocea Biosciences, Inc.
Industry: Medical - Drugs
Company Hunkers Down and So Do We; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Genocea Biosciences, Inc.
Industry: Medical - Drugs
AACR Highlights GEN-011''s Early Glimpse at Activity in Difficult to Treat Tumors
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Genocea Biosciences, Inc.
Industry: Medical - Drugs
2021 Results; TiTAN Looks to Walk Tall; GEN-011 Update at AACR
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Genocea Biosciences, Inc.
Industry: Medical - Drugs
ATLAS Piques Interest From Janssen; GEN-011 Programs Pushes Forward With Data Expected in 1H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Genocea Biosciences, Inc.
Industry: Medical - Drugs
3Q21 Results; TiTAN Stays on Track; Pipeline Visibility Increases with SITC Presentations
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Genocea Biosciences, Inc.
Industry: Medical - Drugs
Company: Genocea Biosciences, Inc.
Industry: Medical - Drugs
2Q21 Results; GEN-011 and GEN-009 Momentum Builds; Updates Expected Throughout Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Genocea Biosciences, Inc.
Industry: Medical - Drugs
TiTAN Takes a Giant Step Forward; First Patient Dosed in Phase 1/2a Trial
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Genocea Biosciences, Inc.
Industry: Medical - Drugs
Company: Genocea Biosciences, Inc.
Industry: Medical - Drugs
1Q21 Results; GEN-009 and GEN-011 Stay the Course; Upcoming Data at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Genocea Biosciences, Inc.
Industry: Medical - Drugs
2020 Results; Progress Continues in Two Key Clinical Programs; COVID Entering Fray?
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Genocea Biosciences, Inc.
Industry: Medical - Drugs
Another Piece to the GEN-009 Puzzle; Watching the Curves Shift
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Genocea Biosciences, Inc.
Industry: Medical - Drugs
3Q20 Results; Rapidly Approaching Important Show-Me Stage for GEN-009 as GEN-011 Program Gets Going
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Genocea Biosciences, Inc.
Industry: Medical - Drugs
GEN-009 Data Continue to Look Encouraging; Key Updates Expected Later This Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Genocea Biosciences, Inc.
Industry: Medical - Drugs
Next GEN-009 Update Solidified For ESMO, But Larger Disclosure Later This Year Likely A Bigger Catalyst
Provider: Stifel Nicolaus Co., Inc.
Analyst: Research Department
Company: Genocea Biosciences, Inc.
Industry: Medical - Drugs
Intriguing First Look From Part B; Broader Look in September
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Genocea Biosciences, Inc.
Industry: Medical - Drugs
2Q20 Results; Eyes on Part B Data Next Week; Target Reduced to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Genocea Biosciences, Inc.
Industry: Medical - Drugs
Next Important GEN-009 Data Shortly; GEN-011 IND Discussions Remain Ongoing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Genocea Biosciences, Inc.
Industry: Medical - Drugs
ATLAS'' Differentiated Profile Gets Another Big Boost
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J